Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer
The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors. In triple negative breast cancer cells this resistance mechanism, namely the Nrf2-regulated “bounce-back” response to proteasome inhi...
Main Authors: | Kamil Lisek, Dawid Walerych, Giannino Del Sal |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Molecular & Cellular Oncology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/23723556.2016.1217967 |
Similar Items
-
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
by: Michael J. Duffy, et al.
Published: (2022-09-01) -
Antitumor Effects of PRIMA-1 and PRIMA-1<sup>Met</sup> (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
by: Paola Menichini, et al.
Published: (2021-01-01) -
A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
by: Sophia Ceder, et al.
Published: (2021-02-01) -
Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications
by: Eziafa I. Oduah, et al.
Published: (2024-04-01) -
Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
by: Jolanda Magri, et al.
Published: (2021-01-01)